COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy

J Infect. 2022 Oct;85(4):436-480. doi: 10.1016/j.jinf.2022.06.011. Epub 2022 Jun 17.

¹ Cardiff University, Cardiff, United Kingdom; All Wales Therapeutics and Toxicology Centre, Cardiff and Vale University Health Board, Llandough, Penlan Road, Cardiff CF64 2XX, United Kingdom. Electronic address: coulsonjm@cardiff.ac.uk.
² National Antiviral Service, Cardiff and Vale University Health Board, United Kingdom.
³ All Wales Therapeutics and Toxicology Centre, Cardiff and Vale University Health Board, Llandough, Penlan Road, Cardiff CF64 2XX, United Kingdom.
⁴ Chief Pharmaceutical Officer for Wales, Health and Social Services Group, Welsh Government, United Kingdom.

No abstract available

Keywords: COVID-19; Nirmatrelvir; Paxlovid; Rebound; Recurrence; Ritonavir.

Publication types